💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Roxadustat

CHEMBL2338329 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
352.3 g/mol
LogP
3.4
Phase
4

Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) used for the treatment of anemia associated with chronic kidney disease. By inhibiting prolyl hydroxylase domain enzymes, it stabilizes HIF-alpha subunits, stimulating erythropoietin production and improving iron absorption and mobilization. Unlike erythropoiesis-stimulating agents, it is orally administered and has demonstrated cardiovascular benefits in clinical trials.

Молекулярная масса

352,3000 g/mol

LogP

3,40

TPSA

109,00 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Cardiovascular Disease Generalized Anxiety Disorder Chronic Kidney Disease Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12

                

                

                
                

                    
InChI

                    
InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H16N2O5

                    

                    
                    

                        
HBD / HBA

                        
3 / 6

                    

                    
                    

                        
Вращаемые Связи

                        
5

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
26

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) used for the treatment of anemia associated with chronic kidney disease. By inhibiting prolyl hydroxylase domain enzymes, it stabilizes HIF-alpha subunits, stimulating erythropoietin production and improving iron absorption and mobilization. Unlike erythropoiesis-stimulating agents, it is orally administered and has demonstrated cardiovascular benefits in clinical trials.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Roxadustat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2338329.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11256664.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.